Motilal Oswal Mutual Fund has significantly reduced its stake in Shaily Engineering Plastics Limited through a substantial disposal of shares, as disclosed in a regulatory filing dated March 17, 2026. The transaction involved multiple schemes of the mutual fund and was conducted through market transactions on March 12, 2026.

Transaction Details

The disposal involved nine schemes of Motilal Oswal Mutual Fund, including Motilal Oswal Balanced Advantage Fund, Motilal Oswal Nifty Microcap 250 Index Fund, Motilal Oswal Small Cap Fund, and six other schemes. The fund disposed of 14,09,072 shares, representing 3.0662% of Shaily Engineering Plastics' total share capital.

Holdings Comparison

The disposal resulted in a significant reduction in Motilal Oswal Mutual Fund's stake in the company. Prior to the transaction, the combined schemes held 38,51,478 shares, representing 8.3810% of the company's equity. Following the disposal, the total holding decreased to 24,42,406 shares, constituting 5.3148% of the total share capital.

Company Information

Shaily Engineering Plastics Limited is listed on both BSE Limited and National Stock Exchange of India Limited. The company's equity share capital stands at 4,59,55,093 shares with a face value of Rs. 02 each. The total diluted share capital, accounting for potential conversion of outstanding convertible securities, is 4,62,28,510 shares.

Regulatory Compliance

The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. Aparna Karmase, Head of Compliance, Legal and Secretarial at Motilal Oswal Asset Management Company Limited, signed the disclosure document. The filing confirms that Motilal Oswal Mutual Fund does not belong to the promoter or promoter group of Shaily Engineering Plastics Limited.

The transaction represents a strategic portfolio adjustment by Motilal Oswal Mutual Fund, reducing its exposure to Shaily Engineering Plastics while maintaining a significant minority stake in the company. The disposal was executed through regular market transactions, ensuring transparency and compliance with regulatory requirements.

Shaily Engineering Plastics Limited has secured a major contract worth approximately ₹423.00 crores from a large domestic pharmaceutical company for the manufacturing and supply of pen injectors. The company announced this significant business development through a regulatory filing under SEBI's Listing Obligations and Disclosure Requirements Regulations, 2015.

Contract Overview

The Manufacturing & Commercial Supply Agreement establishes a comprehensive framework for pen injector production and delivery over an extended timeline. The contract details are as follows:

Strategic Impact

The contract represents a substantial addition to Shaily Engineering Plastics' order book and reinforces the company's capabilities in pharmaceutical device manufacturing. The four-year supply period provides revenue visibility and strengthens long-term customer relationships in the healthcare sector.

The agreement involves a domestic pharmaceutical entity, indicating strong demand within India's growing pharmaceutical market. While the customer's identity remains confidential due to contractual obligations, the partnership with a large domestic pharma company demonstrates Shaily's credibility in the specialized pen injector manufacturing segment.

Compliance and Independence

The company has confirmed that this contract does not involve any related party transactions, ensuring arm's length commercial terms. Additionally, the promoter group has no interest in the entity that awarded the contract, maintaining independence in the business relationship.

This significant contract win positions Shaily Engineering Plastics to capitalize on the expanding pharmaceutical device market while leveraging its manufacturing expertise in precision medical components.